title: Auxological criteria for treating children with idiopathic short stature.
abstract: Children with idiopathic short stature (ISS) may not reach an adult height within their genetic target. In 2003, the United States Food and Drug Administration approved biosynthetic growth hormone (GH) for the treatment of children with ISS whose heights exceeded 2.25 standard deviation scores below the mean and who were considered unlikely to reach a normal adult height. Results of controlled studies have shown that, although GH treatment leads to a substantial increase in adult height, the individual response to therapy is difficult to predict. A number of auxological variables (i.e., age and height at start of treatment, bone age delay, mean predicted height, height velocity and first-year responsiveness) are used in multivariate analyses to predict outcomes. Estimation of target height, predicted adult height and pattern of growth should guide the decision to treat a child with ISS.
authors.affiliation: Servizio di Endocrinologia Pediatrica, Ospedale Microcitemico - ASL Cagliari, Cagliari, Italy.
authors.forename: Sandro
authors.initials: S
authors.lastname: Loche
mesh_terms: D000328:Adult; D000365:Age Determination by Skeleton; D000465:Algorithms; D001827:Body Height; D002648:Child; D002675:Child, Preschool; D006130:Growth Disorders / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone